Inflammation and myeloperoxidase – The next treatment targets in heart failure?

In heart failure with reduced ejection fraction (HFrEF, EF ≤40%), the neurohormonal hypothesis and treatments targeting maladaptive neurohormonal activation represent an unparallelled success. HF with mildly reduced EF (HFmrEF, EF 41–49%) is milder but otherwise largely resembles HFrEF. Post-hoc and sub-group analyses suggest that neurohormonal antagoni sm and modulation may be effective in HFmrEF as well [1]. HF with preserved EF (HFpEF, EF ≥50%) appears clinically largely distinct from HFrEF and HFmrEF, and neurohormonal treatment has not been effective in HFpEF.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research